Utidelone plus capecitabine for metastatic breast cancer
Part of Cancer clinical trials.
This trial tests a combination of two chemotherapy drugs, utidelone and capecitabine, for women with HER2-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman between 18 and 70 years old.
- You have been diagnosed with HER2-negative breast cancer that has come back or spread to other organs.
- You have already received at least one chemotherapy drug like paclitaxel or an anthracycline.
- You have had no more than 3 prior treatments for advanced breast cancer.
- If your cancer is hormone receptor positive, you must have also received a CDK4/6 inhibitor with hormone therapy before it stopped working.
- Your blood counts and organ function need to be within acceptable ranges before starting.
- You cannot be pregnant or breastfeeding, and must use effective birth control if you can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether utidelone combined with bevacizumab can shrink tumors and slow progression in women with advanced HER2-negative breast cancer that has already been treated at least twice. It may help people who have limited options after earlier chemotherapy and/or hormone (endocrine) treatments.
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
This Phase 3 study compares two chemotherapy combinations to treat HER2-negative breast cancer that has spread or is locally advanced. It aims to find which plan works better and has an acceptable side-effect profile for people who have had prior taxane treatment (in earlier-stage settings).
This trial tests a combination of two oral chemotherapy drugs (Utidelone and Capecitabine) for women with triple-negative breast cancer that did not fully disappear after standard chemo before surgery. The goal is to see if this treatment can lower the chance of the cancer coming back.
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
This trial tests if adding UTD2 to capecitabine works better than capecitabine alone for triple-negative breast cancer that didn't completely disappear after chemo. It's for patients who had surgery and are at risk of cancer coming back.
Hear when a new Breast Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.